Pleurocidin KR
General Information
DCTPep ID DCTPep04576
Peptide Name Pleurocidin KR
Sequence GWGSFFRRAAHVGRHVGRAALTHYL
Sequence Length 25
UniProt ID P81941
PubChem CID Not available
Origin Synthetic
Type Synthetic peptide
Classification
ACP Tumor active peptide
Activity Information
Cell Line | Disease | Activity | Assay | Testing Time | Literature |
---|---|---|---|---|---|
HeLa | Human papillomavirus-related endocervical adenocarcinoma | IC50=30.7 ± 2.6 μg/ml | XTT assay | 120 h | 1 |
Hemolytic Activity Not available
Normal (non-cancerous) Cytotoxicity HEK293: IC50=40.1 ± 4.1 µg/ml
Target Not available
Affinity Not available
Mechanism Not available
Structure Information
PDB ID 6RSF
Predicted Structure Not available
(Please note that there is the predicted structure, predicted by AlphaFold)
Helicity Not available
Linear/Cyclic Linear
Disulfide/Other Bond Not available
N-terminal Modification Free
C-terminal Modification Amidation
Other Modification None
Chiral L
Physicochemical Information
Formula C129H192N44O29
Absent amino acids CDEIKMNPQ
Theoretical pI 12.00
Acidic residues 0
Basic residues 7
Polar residues 7
Molecular weight (Average) 2823.22
Molecular weight (Monoisotopic) 2821.49
Common amino acids AGR
Net charge 7
Instability index (II) 48.39
Aliphatic index 70.40
Grand average of hydropathicity (GRAVY) -0.164
Half Life
30 hours (mammalian reticulocytes, in vitro).
>20 hours (yeast, in vivo).
>10 hours (Escherichia coli, in vivo).
Extinction coefficients
Ext. coefficient 6990
Abs 0.1% (=1 g/l) 2.476
Amino acid distribution
Literature Information
Literature 1
Pubmed ID 33247193
Title A pleurocidin analogue with greater conformational flexibility, enhanced antimicrobial potency and in vivo therapeutic efficacy
Doi Not available
Year 2020
Patent
Patent ID Not available
Patent Title Not available
Other Iinformation Not available
Other Published ID Not available
External Code
DBAASP ID 20612